Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (24)
Isaac Pérez-Segura, Alberto Santiago-Balmaseda, Luis Daniel Rodríguez-Hernández, Adriana Morales-Martínez, Hilda Angélica Martínez-Becerril, Paola A. Martínez-Gómez, Karen M. Delgado-Minjares, Citlaltepetl Salinas-Lara, Irma A. Martínez-Dávila, Magdalena Guerra-Crespo, Francisca Pérez-Severiano & Luis O. Soto-Rojas. (2023) PPARs and Their Neuroprotective Effects in Parkinson’s Disease: A Novel Therapeutic Approach in α-Synucleinopathy?. International Journal of Molecular Sciences 24:4, pages 3264.
Crossref
Crossref
Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta, Laura Rodríguez-Pascau & Marc Martinell. (2023) Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International Journal of Molecular Sciences 24:4, pages 3201.
Crossref
Crossref
Upasana Ganguly, Sukhpal Singh, Sasanka Chakrabarti, Adesh K. Saini & Reena V. Saini. 2022. Immunotherapeutics. Immunotherapeutics
381
433
.
Niti Mittal & Rakesh Mittal. (2021) Repurposing old molecules for new indications: Defining pillars of success from lessons in the past. European Journal of Pharmacology, pages 174569.
Crossref
Crossref
Taavi Vanaveski, Svetlana Molchanova, Dan Duc Pham, Annika Schäfer, Ceren Pajanoja, Jane Narvik, Vignesh Srinivasan, Mari Urb, Maria Koivisto, Eero Vasar, Tönis Timmusk, Rimante Minkeviciene, Ove Eriksson, Maciej Lalowski, Tomi Taira, Laura Korhonen, Vootele Voikar & Dan Lindholm. (2021) PGC-1α Signaling Increases GABA(A) Receptor Subunit α2 Expression, GABAergic Neurotransmission and Anxiety-Like Behavior in Mice. Frontiers in Molecular Neuroscience 14.
Crossref
Crossref
Salman Hussain, Ambrish Singh, Harveen Baxi, Bruce Taylor, John Burgess & Benny Antony. (2020) Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes: a meta-analysis of real-world evidence. Neurological Sciences 41:12, pages 3697-3703.
Crossref
Crossref
Shu-Yi Wang, Shey-Lin Wu, Ta-Cheng Chen & Chieh-Sen Chuang. (2020) Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis. International Journal of Environmental Research and Public Health 17:13, pages 4805.
Crossref
Crossref
Efthalia Angelopoulou, Efstratios-Stylianos Pyrgelis & Christina Piperi. (2020) Neuroprotective potential of chrysin in Parkinson's disease: Molecular mechanisms and clinical implications. Neurochemistry International 132, pages 104612.
Crossref
Crossref
Susana Cardoso & Paula I. Moreira. 2020. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases
37
64
.
Sonia Burgaz, Concepción García, Maria Gómez-Cañas, Eduardo Muñoz & Javier Fernández-Ruiz. (2019) Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease. Molecules 24:15, pages 2702.
Crossref
Crossref
Chuhyon Corwin, Anastasia Nikolopoulou, Allen L. Pan, Mariela Nunez-Santos, Shankar Vallabhajosula, Peter Serrano, John Babich & Maria E. Figueiredo-Pereira. (2018) Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. Journal of Neuroinflammation 15:1.
Crossref
Crossref
Concepción García, María Gómez-Cañas, Sonia Burgaz, Belén Palomares, Yolanda Gómez-Gálvez, Cristina Palomo-Garo, Sara Campo, Joel Ferrer-Hernández, Carolina Pavicic, Carmen Navarrete, M. Luz Bellido, Moisés García-Arencibia, M. Ruth Pazos, Eduardo Muñoz & Javier Fernández-Ruiz. (2018) Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor. Journal of Neuroinflammation 15:1.
Crossref
Crossref
Daniela Lecca, Elzbieta Janda, Giovanna Mulas, Andrea Diana, Concetta Martino, Fabrizio Angius, Stefano Spolitu, Maria Antonietta Casu, Gabriella Simbula, Laura Boi, Barbara Batetta, Saturnino Spiga & Anna R Carta. (2018) Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease models. British Journal of Pharmacology 175:16, pages 3298-3314.
Crossref
Crossref
Jéssica Mendes Bonato, Taysa Bervian Bassani, Humberto Milani, Maria Aparecida Barbato Frazão Vital & Rúbia Maria Weffort de Oliveira. (2018) Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats. Experimental Neurology 300, pages 188-200.
Crossref
Crossref
Valerie Joers, Malú G. Tansey, Giovanna Mulas & Anna R. Carta. (2017) Microglial phenotypes in Parkinson’s disease and animal models of the disease. Progress in Neurobiology 155, pages 57-75.
Crossref
Crossref
Jose A. Santiago, Virginie Bottero & Judith A. Potashkin. (2017) Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology. Frontiers in Aging Neuroscience 9.
Crossref
Crossref
Swati Agarwal, Anuradha Yadav & Rajnish Kumar Chaturvedi. (2017) Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochemical and Biophysical Research Communications 483:4, pages 1166-1177.
Crossref
Crossref
Eduardo Maria Normando, Benjamin Michael Davis, Lies De Groef, Shereen Nizari, Lisa A. Turner, Nivedita Ravindran, Milena Pahlitzsch, Jonathan Brenton, Giulia Malaguarnera, Li Guo, Satyanarayana Somavarapu & Maria Francesca Cordeiro. (2016) The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathologica Communications 4:1.
Crossref
Crossref
Gyun Jee Song, Youngpyo Nam, Myungjin Jo, Myungsu Jung, Ja Young Koo, Wansang Cho, Minseob Koh, Seung Bum Park & Kyoungho Suk. (2016) A novel small-molecule agonist of PPAR-γ potentiates an anti-inflammatory M2 glial phenotype. Neuropharmacology 109, pages 159-169.
Crossref
Crossref
Christos V. Rizos, Anastazia Kei & Moses S. Elisaf. (2016) The current role of thiazolidinediones in diabetes management. Archives of Toxicology 90:8, pages 1861-1881.
Crossref
Crossref
Johanna Mäkelä, Timofey V. Tselykh, Jyrki P. Kukkonen, Ove Eriksson, Laura T. Korhonen & Dan Lindholm. (2016) Peroxisome proliferator-activated receptor-γ (PPARγ) agonist is neuroprotective and stimulates PGC-1α expression and CREB phosphorylation in human dopaminergic neurons. Neuropharmacology 102, pages 266-275.
Crossref
Crossref
Rachit Bakshi, Shuchi Mittal, Zhixiang Liao & Clemens R. Scherzer. (2016)
A Feed-Forward Circuit of Endogenous
PGC-1α
and
Estrogen Related Receptor α
Regulates the Neuronal Electron Transport Chain
. Parkinson's Disease 2016, pages 1-9.
Crossref
Crossref
Ana Raquel Esteves, Diana F. Silva, Maria G-Fernandes, Rui Gomes & Sandra Morais Cardoso. 2016. Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease
183
205
.
Jose Santiago & Judith Potashkin. (2014) Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease. Diagnostics 4:4, pages 153-164.
Crossref
Crossref